Flexion Therapeutics (FLXN) Now Covered by Berenberg Bank

Berenberg Bank assumed coverage on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research report issued to clients and investors on Thursday. The brokerage set a “buy” rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Wells Fargo & Co set a $39.00 price objective on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Royal Bank of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, October 29th. Needham & Company LLC lifted their price objective on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 9th. Northland Securities reissued a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a report on Wednesday, October 4th. Finally, Laidlaw reissued a “buy” rating and set a $38.00 price objective (up from $35.00) on shares of Flexion Therapeutics in a report on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $106.25.

Flexion Therapeutics (NASDAQ FLXN) opened at $22.59 on Thursday. The company has a market cap of $872.82, a P/E ratio of -6.44 and a beta of 1.15. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.09). research analysts anticipate that Flexion Therapeutics will post -3.84 EPS for the current year.

In other news, insider Neil Bodick bought 2,700 shares of the stock in a transaction on Tuesday, November 21st. The stock was bought at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the purchase, the insider now directly owns 64,605 shares in the company, valued at $1,582,176.45. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael D. Clayman bought 5,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was purchased at an average price of $23.60 per share, with a total value of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares of the company’s stock, valued at $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Macquarie Group Ltd. boosted its stake in Flexion Therapeutics by 0.6% in the second quarter. Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company’s stock valued at $1,131,000 after acquiring an additional 338 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Flexion Therapeutics by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company’s stock valued at $2,047,000 after acquiring an additional 513 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Flexion Therapeutics by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after acquiring an additional 811 shares in the last quarter. ProShare Advisors LLC boosted its stake in Flexion Therapeutics by 5.5% in the second quarter. ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company’s stock valued at $379,000 after acquiring an additional 982 shares in the last quarter. Finally, Cadence Capital Management LLC boosted its stake in Flexion Therapeutics by 5.1% in the third quarter. Cadence Capital Management LLC now owns 54,002 shares of the specialty pharmaceutical company’s stock valued at $1,306,000 after acquiring an additional 2,612 shares in the last quarter. Institutional investors own 72.78% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/01/flexion-therapeutics-flxn-now-covered-by-berenberg-bank.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply